OSE Immuno: towards an evolution of the Board of Directors
This strategy supports the advanced development of its assets in immuno-oncology (Phase 3 for non-small cell lung cancer) and inflammation (Phase 2 for ulcerative colitis and other potential indications).
In addition, the company reports progress in its first-in-class preclinical programs based on innovative research platforms.
In this context, a strategic evolution of the Board of Directors, including international and pharmaceutical profiles, will be presented at the next Annual General Meeting to reinforce the company's global positioning.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction